Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea ; volume:8 ; number:12 ; day:22 ; month:11 ; year:2018 ; pages:1-10 ; date:12.2018
Blood cancer journal ; 8, Heft 12 (22.11.2018), 1-10, 12.2018
- Creator
-
Pacilli, Annalisa
Rotunno, Giada
Mannarelli, Carmela
Fanelli, Tiziana
Pancrazzi, Alessandro
Contini, Elisa
Mannelli, Francesco
Gesullo, Francesca
Bartalucci, Niccolò
Fattori, Giuditta Corbizi
Paoli, Chiara
Vannucchi, Alessandro M.
Guglielmelli, Paola
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-018-0152-x
- URN
-
urn:nbn:de:101:1-2019010822553816970431
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pacilli, Annalisa
- Rotunno, Giada
- Mannarelli, Carmela
- Fanelli, Tiziana
- Pancrazzi, Alessandro
- Contini, Elisa
- Mannelli, Francesco
- Gesullo, Francesca
- Bartalucci, Niccolò
- Fattori, Giuditta Corbizi
- Paoli, Chiara
- Vannucchi, Alessandro M.
- Guglielmelli, Paola
- SpringerLink (Online service)
Other Objects (12)
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib